🟢 MRNA is trading 3.16% up today driven by FDA regulatory submissions for mRNA-1010 flu vaccine

MRNA is trading at $31.84 (+3.16%) following the announcement of global regulatory submissions for its investigational seasonal influenza vaccine, mRNA-1010.

• Moderna filed for marketing authorization with the FDA, EMA, Health Canada, and Australia's TGA on January 5, 2026.
• The Phase 3 efficacy study achieved 26.6% relative vaccine efficacy across adults 50+, meeting the protocol's superiority criterion.
• The gain reflects investor optimism about expanding Moderna's vaccine portfolio and potential 2027 product launches.